REFERENCES
- Menichetti F. Current and emerging serious Gram-positive infections. Clin Microbiol Infect 2005; 11 (Suppl. 3): 22-28.
- Moellering RC. Linezolid: the first oxazolidinone antimi-crobial. Ann Intern Med 2003; 138: 135–42.
- Stevens DL, Dotter B, Madaras-Kelly A. A review of line-zolid: the first oxazolidinone antibiotic. Expert Rev Anti-Infective Ther 2004; 2: 51–59.
- Eliopoulos GM. Quinupristin/dalfopristin and linezolid: ev-idence and opinions. Clin Infect Dis 2003; 36: 473–481.
- Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ven-tilator-associated pneumonia: retrospective analysis of two dou-ble-blind studies comparing linezolid with vancomycin. Intensive Care Med. 2004; 30 (3): 388–94.
- Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C, (Linezolid CSSTI study group). Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. An-timicrob Agents Chemother 2005; 49: 2260–2266
- Lipsky BA, Itani K, Norden C, (Linezolid diabetic foot in-fection study group). Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004; 38: 17–24.
- Rubinstein E, Cammarata S, Oliphant T, Wunderink R, (Linezolid nosocomial pneumonia study group). Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized Patients with nosocomial pneumonia: a randomized, double-blind multicentre study. Clin Infect Dis 2001; 32: 402–412.
- WilCOX M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother 2004; 53: 335–342.
- Craven DE, Palladino R, McQuillen DP: Healthcare-asso-ciated pneumonia in adults: management principles to improve outcomes. Infect Dis North Am 2004; 18: 939–962.
- Sharpe JN, Shively EH, Polk HC Jr. Clinical and eco-nomic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower extremity skin and soft tissue infections caused by methicillin-resistant Staphylo-coccus aureus. Am J Surg 2005; 189: 425–428.
- Nathwani D, Li JZ, Balan DA, Willke RJ, Rittenhouse BE, Mozaffari E, et al. An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in seri-ous Gram-positive bacterial infections: the importance of treat-ment setting in evaluating treatment effects. Int J Antimicrob Agents 2004; 23: 315–324.
- Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptite or 13-lactam for treatment of gram—positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008; 8: 53–66.